Regulation of cytokine receptor signaling by SOCS1

Immunological Reviews

Volumn 192, Issue , 2003, Pages 196-211

  Ilangumaran, Subburaj ^a   Rottapel, Robert ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; JANUS KINASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL;

ANIMALS; CARRIER PROTEINS; CELL LINEAGE; MICE; MODELS, BIOLOGICAL; ONCOGENE PROTEINS, FUSION; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, CYTOKINE; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEINS;

EID: 0038239874     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2003.00020.x     Document Type: Review

References (107)

1. Watowich SS, Wu H, Socolovsky M, Klingmuller U, Constantinescu SN, Lodish HF. Cytokine receptor signal transduction and the control of hematopoietic cell development. Annu Rev Cell Dev Biol 1996;12:91-128.
2. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002;109:S121-S131.
3. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene 2000;19:5662-5679.
4. Naka T, Fujimoto M, Kishimoto T. Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. Trends Biochem Sci 1999;24:394-398.
5. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol 2000;18:143-164.
6. Starr R, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997;387:917-921.
7. Yoshimura A, et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 1995;14:2816-2826.
8. Endo TA, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997;387:921-924.
9. Naka T, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997;387:924-929.
10. Ohya K, et al. SOCS-1/JAB/SSI-1 can bind to and suppress Tec protein-tyrosine kinase. J Biol Chem 1997;272:27178-27182.
11. De Sepulveda P, Okkenhaug K, Rose JL, Hawley RG, Dubreuil P, Rottapel R. Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. EMBO J 1999;18:904-915.
12. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002;2:1-7.
13. Kile BT, Schulman BA, Alexander WS, Nicola NA, Martin HM, Hilton DJ. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci 2002;27:235-241.
14. Naka T, et al. Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc Natl Acad Sci USA 1998;95:15577-15582.
15. Starr R, et al. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci USA 1998;95:14395-14399.
16. Marine JC, et al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 1999;98:609-616.
17. Metcalf D, et al. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 2000;405:1069-1073.
18. Marine JC, et al. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 1999;98:617-627.
19. Roberts AW, et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci USA 2001;98:9324-9329.
20. Saito H, Morita Y, Fujimoto M, Narazaki M, Naka T, Kishimoto T. IFN regulatory factor-1-mediated transcriptional activation of mouse STAT-induced STAT inhibitor-1 gene promoter by IFN-gamma. J Immunol 2000;164:5833-5843.
21. Narazaki M, et al. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc Natl Acad Sci USA 1998;95:13130-13134.
22. Nicholson SE, et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distract mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J 1999;18:375-385.
23. Yasukawa H, et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 1999;18:1309-1320.
24. Sakamoto H, et al. A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons. Blood 1998;92:1668-1676.
25. O'Keefe GM, Nguyen VT, Ping Tang LL, Benveniste EN. IFN-gamma regulation of class II transactivator promoter IV in macrophages and microglia: involvement of the suppressors of cytokine signaling-1 protein. J Immunol 2001;166:2260-2269.
26. Sakamoto H, Kinjyo I, Yoshimura A. The Janus kinase inhibitor, Jab/SOCS-1, is an interferon-gamma inducible gene and determines the sensitivity to interferons. Leuk Lymphoma 2000;38:49-58.
27. Song MM, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem 1998;273:35056-35062.
28. Alexander WS, et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999;98:597-608.
29. Bustelo XR. Regulatory and signaling properties of the Vav family. Mol Cell Biol 2000;20:1461-1477.
30. Abe K, Whitehead IP, O'Bryan JP, Der CJ. Involvement of NH(2)-terminal sequences in the negative regulation of Vav signaling and transforming activity. J Biol Chem 1999;274:30410-30418.
31. Aghazadeh B, Lowry WE, Huang XY, Rosen MK. Structural basis for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation. Cell 2000;102:625-633.
32. Katzav S, Martin-Zanca D, Barbacid M. Vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J 1989;8:2283-2290.
33. De Sepulveda P, Ilangumaran S, Rottapel R. Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. J Biol Chem 2000;275:14005-14008.
34. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 1991;66:161-171.
35. Raffel GD, Parmar K, Rosenberg N. In vivo association of v-Abl with Shc mediated by a non-phosphotyrosine- dependent SH2 interaction. J Biol Chem 1996;271:4640-4645.
36. Schmandt R, Liu SK, McGlade CJ. Cloning and characterization of mPAL, a novel Shc SH2 domain-binding protein expressed in proliferating cells. Oncogene 1999;18:1867-1879.
37. Oligino L, et al. Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain. J Biol Chem 1997;272:29046-29052.
38. Joung I, Strominger JL, Shin J. Molecular cloning of a phosphotyrosine-independent ligand of the p56lck SH2 domain. Proc Natl Acad Sci USA 1996;93:5991-5995.
39. Dutartre H, Harris M, Olive D, Collette Y. The human immunodeficiency virus type I Nef protein binds the Src- related tyrosine kinase Lck SH2 domain through a novel phosphotyrosine independent mechanism. Virology 1998;247:200-211.
40. Nantel A, Mohammad-Ali K, Sherk J, Posner BI, Thomas DY. Interaction of the Grb10 adapter protein with the Raf1 and MEK1 kinases. J Biol Chem 1998;273:10475-10484.
41. Morra M, et al. Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells. EMBO J 2001;20:5840-5852.
42. Poy F, et al. Crystal structures of the XLP protein SAP reveal a class of SH2 domains with extended, phosphotyrosine-independent sequence recognition. Mol Cell 1999;4:555-561.
43. Kamura T, et al. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev 1998;12:3872-3881.
44. Zhang JG, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to Elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA 1999;96:2071-2076.
45. Kamura T, Brower CS, Conaway RC, Conaway JW. A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase. J Biol Chem 2002;277:30388-30393.
46. Tyers M, Rottapel R. VHL: a very hip ligase. Proc Natl Acad Sci USA 1999;96:12230-12232.
47. Iwai K, et al. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 1999;96:12436-12441.
48. Kamura T, et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999;284:657-661.
49. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin - protein ligase activity. Genes Dev 1999;13:1822-1833.
50. Verdier F, et al. Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STATS) activation. Possible involvement of the ubiquitinated Cis protein. J Biol Chem 1998;273:28185-28190.
51. Kamura T, et al. MUF1, a novel Elongin BC-interacting leucine-rich repeat protein that can assemble with CUl5 and Rbx1 to reconstitute a ubiquitin ligase. J Biol Chem 2001;276:29748-29753.
52. Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG. SOCS-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol 2001;21:3547-3557.
53. Kamizono S, et al. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J Biol Chem 2001;276:12530-12538.
54. Ungureanu D, Saharinen P, Junttila I, Hilton DJ, Silvennoinen O. Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol Cell Biol 2002;22:3316-3326.
55. Rottapel R, et al. The tumor suppressor activity of SOCS-1. Oncogene 2002;21:4351-4362.
56. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002;277:42394-42398.
57. Zhang JG, et al. The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc Natl Acad Sci USA 2001;98:13261-13265.
58. Jegahan AG, Wu H. Regulation of Socs gene expression by the protooncoprotein GFI-1B: two routes for STATS target gene induction by erythropoietin. J Biol Chem 2002;277:2345-2352.
59. Yoshikawa H, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001;28:29-35.
60. Gregorieff A, Pyronnet S, Sonenberg N, Veillette A. Regulation of SOCS-1 expression by translational repression. J Biol Chem 2000;275:21596-21604.
61. Siewert E, Muller-Esterl W, Starr R, Heinrich PC, Schaper F. Different protein turnover of interleukin-6-type cytokine signalling components. Eur J Biochem 1999;265:251-257.
62. Hanada T, et al. A mutant form of JAB/SOCS1 augments the cytokine-induced JAK/STAT pathway by accelerating degradation of wild-type JAB/CIS family proteins through the SOCS-box. J Biol Chem 2001;276:40746-40754.
63. Chen XP, et al. Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci USA 2002;99:2175-2180.
64. Toniato E, Chen XP, Losman J, Flati V, Donahue L, Rothman P. TRIM8/GERP RING finger protein interacts with SOCS-1. J Biol Chem 2002;277:37315-37322.
65. Metcalf D, Mifsud S, Di Rago L, Nicola NA, Hilton DJ, Alexander WS. Polycystic kidneys and chronic inflammatory lesions are the delayed consequences of loss of the suppressor of cytokine signaling-1 (SOCS-1). Proc Natl Acad Sci USA 2002;99:943-948.
66. Simon AR, Takahashi S, Severgnini M, Fanburg BL, Cochran BH. Role of the JAK-STAT pathway in PDGF-stimulated proliferation of human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2002;282:L1296-L1304.
67. Peeters P, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997;290:2535-2540.
68. Lacronique V, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997;278:1309-1312.
69. Schwaller J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 1998;17:5321-5333.
70. Hirota S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580.
71. Lupher ML, Rao N, Eck MJ, Band H. The Cbl protooncoprotein: a negative regulator of immune receptor signal transduction. Immunol Today 1999;20:375-382.
72. Danial NN, et al. Direct interaction of Jak1 and v-Abl is reqiured for v-Abl-induced activation of STATs and proliferation. Mol Cell Biol 1998;18:6795-6804.
73. Danial NN, Rothman P. JAK-STAT signaling activated by Abl oncogenes. Oncogene 2000;19:2523-2531.
74. Gilks CB, Bear SE, Grimes HL, Tsichlis PN. Progression of interleukin-2 (IL-2)-dependent rat T cell lymphoma lines to IL-2-independent growth following activation of gene (gfi-1) encoding a novel zinc finger protein. Mol Biol Cell 1993;13:1759-1768.
75. Zornig M, Schmidt T, Karsunky H, Grzeschiczek A, Moroy T. Zinc finger protein GFI-1 cooperates with myc and pim-1 in T-cell lymphomagenesis by reducing the requirements for IL-2. Oncogene 1996;12:1789-1801.
76. Schmidt T, Karsunky H, Gau E, Zevnik B, Elsasser HP, Moroy T. Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis. Oncogene 1998;17:2661-2667.
77. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-264.
78. Ilangumaran S, et al. A positive regulatory role for SOCS1 (suppressor of cytokine signaling 1) in interferon gamma-induced MHC class II expression in fibroblasts. J Immunol 2002;169:5010-5020.
79. Meraz MA, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996;84:431-442.
80. Muhlethaler-Mottet A, Di Berardino W, Otten LA, Mach B. Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity 1998;8:157-166.
81. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 2001;19:331-373.
82. Roche PA, Marks MS, Cresswell P. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 1991;354:392-394.
83. Nguyen H, Ramana CV, Bayes J, Stark GR. Roles of phosphatidylinositol 3′-kinase in interferon-{gamma}-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression. J Biol Chem 2001;276:33361-33368.
84. Greenhalgh CJ, et al. Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem 2002;277:40181-40184.
85. Hochstrasser M. Evolution and function of ubiquitin-like protein-conjugation systems. Nat Cell Biol 2000;2:E153-E157.
86. Hochstrasser M. SP-RING for SUMO: new functions bloom for a ubiquitin-like protein. Cell 2001;107:5-8.
87. Baird PN, Gerstein RM, Berg LJ. The role of cytokine receptor signaling in lymphocyte development. Curr Opin Immunol 1996;11:157-166.
88. Marrack P, et al. Homeostasis of alpha beta TCR+ T cells. Nat Immunol 2000;1:107-111.
89. Zuniga-Pflucker JC, Lenardo MJ. Regulation of thymocyte development from immature progenitors. Curr Opin Immunol 1996;8:215-224.
90. Rodewald HR, Ogawa M, Haller C, Waskow C, DiSanto JP. Pro-thymocyte expansion by c-kit and the common cytokine receptor gamma chain is essential for repertoire formation. Immunity 1997;6:265-272.
91. Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 2001;14:105-110.
92. Trop S, De Sepulveda P, Zuniga-Pflucker JC, Rottapel R. Overexpression of suppressor of cytokine signaling-1 impairs pre-T-cell receptor-induced proliferation but not differentiation of immature thymocytes. Blood 2001;97:2269-2277.
93. Schmidt T, Karsunky H, Rodel B, Zevnik B, Elsasser HP, Moroy T. Evidence implicating Gfi-1 and Pim-1 in pre-T-cell differentiation steps associated with beta-selection. EMBO J 1998;17:5349-5359.
94. Fujimoto M, et al. Defective thymocyte development and perturbed homeostasis of T cells in STAT-induced STAT inhibitor-1/suppressors of cytokine signaling-1 transgenic mice. J Immunol 2000;165:1799-1806.
95. Gresser I, et al. Electrophoretically pure mouse interferon inhibits growth, induces liver and kidney lesions, and kills suckling mice. Am J Pathol 1981;102:396-402.
96. Bullen DV, Darwiche R, Metcalf D, Handman E, Alexander WS. Neutralization of interferon-gamma in neonatal SOCS1-/-mice prevents fatty degeneration of the liver but not subsequent fatal inflammatory disease. Immunology 2001;104:92-98.
97. Losman JA, Chen XP, Hilton D, Rothman P. Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. J Immunol 1999;162:3770-3774.
98. Sporri B, Kovanen PE, Sasaki A, Yoshimura A, Leonard WJ. JAB/SOCS1/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling. Blood 2001;97:221-226.
99. Murphy KM, et al. Signaling and transcription in T helper development. Annu Rev Immunol 2000;18:451-494.
100. Dickensheets HL, Venkataraman C, Schindler U, Donnelly RP. Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. Proc Natl Acad Sci USA 1999;96:10800-10805.
101. Venkataraman C, Leung S, Salvekar A, Mano H, Schindler U. Repression of IL-4-induced gene expression by IFN-gamma requires Stat1 activation. J Immunol 1999;162:4053-4061.
102. Diehl S, et al. Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. Immunity 2000;13:805-815.
103. Egwuagu CE, Yu CR, Zhang M, Mahdi RM, Kim SJ, Gery I. Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance. J Immunol 2002;168:3181-3187.
104. Eyles JL, Metcalf D, Grusby MJ, Hilton DJ, Starr R. Negative regulation of interleukin-12 signaling by suppressor of cytokine signaling-1. J Biol Chem 2002;277:43735-43740.
105. Matsuda T, Yamamoto T, Kishi H, Yoshimura A, Muraguchi A. SOCS-1 can suppress CD3zeta- and Syk-mediated NF-AT activation in a non-lymphoid cell line. FEBS Lett 2000;472:235-240.
106. Li S, et al. Cytokine-induced Src homology 2 protein (CIS) promotes T cell receptor-mediated proliferation and prolongs survival of activated T cells. J Exp Med 2000;191:985-994.
107. Nyman TA, Matikainen S, Sareneva T, Julkunen I, Kalkkinen N. Proteome analysis reveals ubiquitin-conjugating enzymes to be a new family of interferon-alpha-regulated genes. Eur J Biochem 2000;267:4011-4019.